Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APG-115 Alone or With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors
NCT05701306Phase 2Recruiting
- Sponsor
- Ascentage Pharma
- Start
- Feb 2023
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of alrizomadlin and lisaftoclax in neuroblastoma and solid tumor (2 arms), sponsored by Ascentage Pharma. Primary endpoints: Dose Limiting Toxicity at 21 days and Treatment-Emergent Adverse Events at 12 months. Started Feb 2023; status: recruiting.
02
Drugs
alrizomadlinlisaftoclax
03
Conditions
neuroblastomasolid tumor
Beyond the preview
Go deeper on NCT05701306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05701306.